Health & Environment
US FDA approves AbbVie's tavapadon for Parkinson's disease
The Hindu15h
THE BRIEF
1
The U.S. Food and Drug Administration approved AbbVie's once-a-day pill tavapadon, branded as Juvmo, for treating Parkinson's disease in adults.
2
The approval is based on late-stage trial data showing improved symptoms, while common side effects included nausea, dizziness, and headache.
3
AbbVie acquired the drug through its $8.7 billion purchase of Cerevel Therapeutics in 2023, targeting over $5 billion in combined Parkinson's sales.